Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults
Ebola virus (EBOV) epidemics pose a major public health risk. There currently is no licensed human vaccine against EBOV. The safety and immunogenicity of a recombinant EBOV glycoprotein (GP) nanoparticle vaccine formulated with or without Matrix-M adjuvant were evaluated to support vaccine developme...
שמור ב:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | אנגלית |
| יצא לאור: |
2019
|
| גישה מקוונת: | https://doi.org/10.1093/infdis/jiz518 https://academic.oup.com/jid/article-pdf/222/4/572/33524591/jiz518.pdf |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|